Searching…
Ambisome (Amphotericin B) Company: Astellas Application No.: 050740 Approval Date: 8/11/1997 Approval Letter (s) and Medical Review Part 1) (PDF) Medical Review Part 2 (PDF) Medical Review Part...
Drug Administration, Rockville, Maryland In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Ad...
Detailed FDA approval information for AmBisome, including regulatory status, product details, and official drug labeling information.
Deerfield, IL and Foster City, CA -- July 5, 2000 Fujisawa Healthcare, Inc. and Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved the antifungal drug AmBisome® [ ...
In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Administration.
Pediatric patients, age 1 month to 16 years, with presumed fungal infection (empirical therapy), confirmed systemic fungal infections or with visceral leishmaniasis have been successfully treated...
The pharmacokinetics of amphotericin B after administration of AmBisome in pediatric and elderly patients have not been studied; however, AmBisome has been used in pediatric and elderly patients (see DESCRIPTION OF CL...
Describe approved amphotericin B drug products and discuss challenges in developing generic amphotericin B liposome. • Explain FDA’s latest revision to the product- specific guidance...
Deerfield, IL and Foster City, CA -- February 10, 2000. Fujisawa Healthcare, Inc. and Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Food and Drug Administration (FDA) has approved a supplemental new dru...
商品名:AMBISOME,活性成分:AMPHOTERICIN B,申请号:050740,申请人:ASTELLAS
